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Tbjectives: Patients receiving mechanical circulatory support are at risk for the
evelopment of heparin-induced thrombocytopenia due to the prolonged postoper-
tive use of heparin. We evaluated their antibody status and outcome.
ethods: Between 2003 and 2004, 115 patients received mechanical circulatory sup-
ort for more than 5 days. Blood samples from postoperative day 7 were retrospec-
ively analyzed for anti–platelet factor 4/heparin antibodies and heparin-induced
latelet activation.
esults: Overall, 12 (10.6%) patients had heparin-induced thrombocytopenia as
efined by in vitro platelet activation, 28 (24.8%) had nonactivating antibodies, and
3 (64.6%) were classified as negative for antibodies. Patients positive for heparin-
nduced thrombocytopenia had the highest levels of anti–platelet factor 4/heparin
mmunoglobulin G antibodies. Freedom from thromboembolism was 33%, 33%,
nd 16% at 1, 3, and 6 months for positive patients, 77%, 68%, and 55% for negative
atients (P  .001), and 70%, 53%, and 53% for patients with nonactivating
ntibodies (P  .068), respectively. The relative risk for thromboembolism in
ntibody positive patients peaked in the first month of support (odds ratio 7.46, P 
002). Independent risk factors for thromboembolic events included higher anti–
latelet factor 4/heparin antibody titers, female gender, and higher fibrinogen levels.
onclusion: Heparin-induced thrombocytopenia was more prevalent in patients
eceiving mechanical circulatory support than in other cardiac patients. Frequent
ntibody screening is recommended due to the increased risk of thromboembolism.
eparin alternatives should be subjected to clinical trials in these high-risk patients.
eparin is a standard anticoagulant, but adverse events associated with its use
are frequent. Antibodies can be formed against complexes of platelet factor
4 (PF4), a self protein, and heparin. The resulting PF4/heparin/immuno-
lobulin G (IgG) complexes then induce platelet activation, which, in turn, results
n arterial and venous thrombus formation.1,2 Anti-PF4/heparin antibodies are
etected in more than 50% of patients undergoing cardiac surgery,3-6 although the
linical relevance remains debated. Only 1% to 3% of patients are reported to have
linically relevant heparin-induced thrombocytopenia (HIT),4,5 a syndrome based
n clinical and laboratory signs: that is, thromboembolism, decrease of platelet
ounts, and anti-PF4/heparin antibodies.7 However, additional consideration is
arranted in patients receiving mechanical circulatory support (MCS). These pa-
ients are commonly exposed to prolonged use of heparin before surgery and, unlike
ther cardiac patients, invariably receive heparin after surgery for several weeks.
he immune response leading to anti-PF4/heparin antibody formation may thus be
nduced for a longer biologically active time. Subsequently, HIT antibodies may
ven act in concert with other thrombogenic factors inherent to mechanical support,
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 6 1373
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CSPuch as platelet and coagulation activation. Selected studies
uggest that this may indeed be true, but a detailed
ssessment of the interrelationship between platelet
ounts, anti-PF4/heparin antibodies, coagulation moni-
oring, and clinical events has not been performed.
To better manage these critically ill patients by choosing
ppropriate anticoagulation, we sought to test our clinical
bservation that HIT is an underappreciated problem with
herapeutic challenges and serious consequences. Thus, for
atients undergoing MCS, we sought to (1) evaluate prev-
lence, amount, and Ig classes of anti-PF4/heparin antibod-
es, (2) provide an assessment of heparin-induced platelet
ctivation to diagnose or rule out HIT, and (3) determine the
mpact of anti-PF4/heparin antibodies on clinical outcomes.
ethods
atients and Devices
rom January 2003 to December 2004, 126 patients were placed
n MCS at the Heart Center NRW Bad Oeynhausen, Germany,
sing 10 different left ventricular or biventricular devices (Appen-
ix E1). Device selection criteria and management have been
ublished previously.8 Patients with a support time of 5 days or
ewer because of death due to circulatory collapse (n  10) or
eart transplantation (n  1) were not included in this study,
eaving 115 patients. Patient characteristics are summarized in
able E1. Data were extracted from the institutional data base
ndorsed by The Institutional Review Board of the Heart Center,
Abbreviations and Acronyms
aPTT  activated partial thromboplastin
time
CAA  column agglutination assay
EIA  enzyme immunoassay
HGW  Hansestadt Greifswald
HIPA  heparin-induced platelet
activation assay
HIPA&id/ IgG  heparin-induced platelet
activation assay positive or
indeterminate with IgG titers of
OD  1.0
HIPA/IgG,A,M heparin-induced
thrombocytopenia platelet
activation assay negative and
IgG, IgA, and IgM antibodies
HIT  heparin-induced
thrombocytopenia
Ig  immunoglobulin
INR  international normalized ratio
MCS mechanical circulatory support
OD  optical density
PF4  platelet factor 4
POD  postoperative day
TIA  transient ischemic attackad Oeynhausen, Germany. F
374 The Journal of Thoracic and Cardiovascular Surgery ● JunThromboembolism was confirmed or excluded on clinical sta-
us by computed tomography, angiography, and/or Doppler ultra-
onography. Patients who died while receiving MCS underwent
utopsy by a pathologist experienced in cardiovascular diseases
nd devices.
nticoagulation Protocol and Blood Sampling
ll patients were receiving heparin before surgery, and all patients
ad a likely history of heparin exposure during previous hospital-
zations. Only unfractionated heparin obtained from porcine intes-
inal mucosa was used. Assist devices were implanted during
ardiopulmonary bypass with heparin used for anticoagulation
activated clotting time  400 seconds). Heparin was reversed by
rotamine and then withheld for 24 hours or as long as chest tube
rainage remained greater than 100 mL/h. Thereafter, all patients
eceived heparin for several weeks postoperatively (activated par-
ial thromboplastin time [aPTT] 40-60 seconds) and were then
witched to oral phenprocoumon (international normalized ratio
INR] 2.5-3.5). Antiplatelet agents, that is, aspirin or clopidogrel,
ere given in selected patients beginning not before the second
ostoperative month.
Blood samples were obtained daily for platelet counts and
tandard coagulation assays, including aPTT, INR, fibrinogen, and
-dimers. Tests for the presence of anti-PF4/heparin antibodies
ere ordered in cases of suspected HIT at the attending physi-
ian’s discretion. Indications were otherwise unexplained throm-
ocytopenia and/or the occurrence of thromboembolism. Addi-
ional blood samples were collected on postoperative days (POD)
to 7 in citrated tubes, centrifuged, and stored at 80°C. These
amples were used for retrospective tests of anti-PF4/heparin an-
ibodies and heparin-induced platelet activation. All samples were
btained from an arterial line after 10 mL of blood was withdrawn
rom the line.
nti-PF4/Heparin Antibodies
he presence of antibodies to the heparin/PF4 platelet protein
omplex was tested by the polyspecific enzyme immunoassay
TI-PF4 (EIA GTI) (Genetic Testing Institute, Waukesha, Wis)
ith an optical density (OD) of 0.5 as cutoff point. All stored
lood samples from PODs 5 to 7 were also tested by EIA GTI and
dditionally by the column agglutination assay (CAA) (DiaMed
iagnostika, Bensheim, Germany). The latter test provides a semi-
uantitative signal ranging from 0 (no antibodies detected) to 3
highest level of particle agglutination). EIA GTI and/or CAA-
ositive blood probes were sent blinded to a reference laboratory
or evaluation by custom-made mono-specific EIA (EIA Hanse-
tadt Greifswald [HGW]) for Ig classes and by heparin-induced
latelet activation assay (HIPA), as previously described.9 The
ombined use of HIPA with mono-specific EIA was validated for
iagnosing HIT in previous studies.10 Specifically, antibodies test-
ng positive by the HIPA were considered clinically relevant HIT
ntibodies. If the HIPA showed heparin-independent platelet acti-
ation, the test was designated indeterminate. Only in those cases,
n IgG class antibody titer of OD greater than 1.0 defined clinically
elevant HIT antibodies. Conversely, HIPA negative antibodies
ere considered clinically not relevant regardless of their IgG titer.
inally, all IgA and IgM antibodies were considered irrelevant.
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Pata Analysis
ata are presented as percentage, mean  standard deviation, or
5% confidence interval. Several demographic, procedural, and
aboratory variables were considered as potential risk factors for
hrombotic events (Appendix E2). Univariate comparisons were
ade by the Mann-Whitney test, Student t test, Kendall tau, 2
est, or 1-way analysis of variance with Bonferroni post-hoc test-
ng, as appropriate. Those factors with a statistically significant
ifference (P  .10) were then included stepwise (forward and
ackward) in a multivariate logistic regression with thrombotic
vent as the dependent variable. The model was built with 64
andomly selected patients and then validated on the remaining 51
atients. Variables were retained in the model at a significance
evel of P  .05. The distribution of clinical events over time was
nalyzed by nonparametric Kaplan-Meier estimates, followed by a
og-rank test. Clinical events per time interval were compared with
he 2 test, and their relative risk was calculated. Predictive capa-
ilities of various anti-PF4/heparin antibody tests with respect to
he occurrence of thromboembolism were estimated by Bayesian
igure 1. Sequence of anti-PF4/heparin antibody testing. MCS,
echanical circulatory support; EIA GTI, polyspecific anti-PF4/
eparin antibody enzyme immunoassay; EIA HGW, monospecific
nti-PF4/heparin antibody enzyme immunoassay; HIPA, heparin-
nduced platelet activation assay; HIT, heparin-induced thrombo-
ytopenia; POD, postoperative day; Ig, immunoglobulin.
ABLE 1. Amount and Ig classes of anti-PF4/heparin antib
EIA GTI (OD) IgG (OD)
IPA&id/IgG 1.810 0.91*† (n 12) 1.508 0.41*† (n
IPA/IgG,A,M 0.852 0.52 (n 28) 0.652 0.39 (n 28
IT negative 0.397 0.31 (n 73) 0.244 0.12 (n 34
IA GTI (OD), Titer of anti–platelet factor 4/heparin antibodies by polyspec
f heparin-induced platelet activation (yes/no); HIPA&id/IgG, heparin
D  1.0; HIPA/IgG,A,M heparin-induced thrombocytopenia platelet achrombocytopenia. *HIPA&id/IgG versus HIPA/IgG,A,M, P  .001. †HIP
The Journal of Thoraciceasoning. All analyses were performed with SPSS 12.0 (SPSS
nc, Chicago, Ill).
esults
nti-PF4/Heparin Antibodies
omplete information on the presence of anti-PF4/heparin
ntibodies by POD 7 was available in 113 of 115 patients;
ll of them at least briefly received heparin after surgery. At
OD 7, 39 of 113 (34.5%) blood probes tested negative by
IA GTI and CAA, including 5 patients subsequently be-
oming EIA GTI positive (PODs 12, 14, 18, 30, and 240,
espectively). Seventy-four (65%) tested positive for anti-
F4/heparin antibodies by EIA GTI and/or CAA. These
amples were further tested by mono-specific EIA HGW
nd HIPA. Overall, a group of 12 (10.6%) patients either
ad a positive HIPA test (n  10) and anti-PF4/heparin
gG antibodies or an indeterminate HIPA test and anti-
F4/heparin IgG antibodies with an OD greater than 1.0
HIPA&id/IgG). Another 28 (24.8%) patients were
IPA negative but had anti-PF4/heparin antibodies of IgG,
gA, or IgM classes (HIPA/IgG,A,M). A third group of
3 (64.6%) patients were anti-PF4/heparin antibody nega-
ive (Figure 1, Table 1). Anti-PF4/heparin IgA and IgM
evels did not differ significantly between HIPA&id/
gG and HIPA/IgG,A,M patients (Table 1).
linical Diagnosis and Treatment of
eparin-Induced Thrombocytopenia
n 51 of 115 patients, anti-PF4/heparin antibodies were as-
essed at the attending physician’s discretion to diagnose or
o rule out HIT (Figure 1). Tests were ordered at a median
f 5 days (range 26-279 days), predominantly due to a low
latelet count for at least 2 days (76,000/mL 52,000/mL).
n one case, a thromboembolic event (limb ischemia) pre-
eded assessment of antibody status. Of note, the majority
f tests for anti-PF4/heparin antibodies were ordered in the
econd half of the study period (38 vs 13 cases), likely due
o an enhanced awareness of HIT.
Among 51 patients tested for HIT, 12 patients (24%) had
nti-PF4/heparin antibodies by the polyspecific EIA GTI
uring their hospital stay. Of these, 6 patients were retro-
pectively confirmed by HIPA&id/IgG. One patient
s and heparin-induced platelet activation
IgA (OD) IgM (OD) HIPA (pos/ neg)
0.872 0.65† (n 12) 0.611 0.41† (n 12) 10/2 (n 12)
0.543 0.45 (n 28) 0.397 0.29 (n 28) 0/28 (n 28)
0.182 0.09 (n 34) 0.201 0.08 (n 34) 0/39 (n 34)
zyme immunoassay; OD, optical density; Ig, immunoglobulin; HIPA, status
ed platelet activation assay positive or indeterminate with IgG titers of
on assay negative and IgG, IgA, and IgM antibodies; HIT, heparin-inducedodie
12)
)
)
ific en
-induc
tivatiA&id/lgG versus HIT negative, P  .001.
and Cardiovascular Surgery ● Volume 131, Number 6 1375
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CSP
merged as HIPA/IgG,A,M and 5 patients were found
o be HIT negative.
Heparin was suspended in 12 patients once they were
ound positive by the EIA GTI, and lepirudin or antiplatelet
cetylsalicylic acid and/or epoprostenol was substituted.
espite alternative anticoagulation, all 6 patients later con-
rmed as HIPA&id/IgG had thromboembolic events
Table E2). The 1 patient with HIPA/IgG,A,M status
ad cerebral bleeding (POD 9) while receiving lepirudin,
nd 1 HIT negative patient receiving epoprostenol had a
erebral transitory ischemic attack (TIA) with no residuals
POD 8). Furthermore, 1 HIT negative patient had a TIA
igure 2. A, Platelet counts during mechanical support. B, Rela-
ive platelet counts (percent change from baseline) during me-
hanical support. Numbers in parentheses indicate patients for
hom data are available. Vertical bars indicate 1 SD. Solid line
—), Heparin-induced platelet activation assay positive or inde-
erminate with IgG titers of OD > 1.0; solid line with squares
––), heparin-induced thrombocytopenia negative; solid line with
riangles (–‘–), heparin-induced thrombocytopenia platelet activa-
ion assay negative and IgG, IgA, or IgM antibodies. *P < .05.ong after epoprostenol treatment while receiving phenproc- b
376 The Journal of Thoracic and Cardiovascular Surgery ● Junumon (POD 133) and 3 HIT negative patients remained
ree of thromboembolism.
latelet Counts and Standard Coagulation Monitoring
here was a transient drop in platelet count until POD 7 in
ll groups, and absolute platelet counts recovered with no
urther period of thrombocytopenia thereafter (Figure 2, A).
nterestingly, when computed as percent change from
aseline, HIPA&id/IgG patients revealed 3-fold
igher relative platelet counts between POD 10 and POD
5 as compared with HIT negative or HIPA/IgG,A,M
atients (Figure 2, B).
Standard coagulation tests during MCS did not provide
onclusive evidence that blood coagulation differed with
espect to the anti-PF4/heparin antibody status (Table E3).
here was a trend toward higher levels of D-dimers between
ODs 5 to 7 in HIPA&id/IgG patients, indicating their
ypercoagulability (HIPA&id/IgG, HIPA/IgG,A,M,
nd HIT negative; 1183 975, 1460 1631, and 843 837,
espectively; P  .042). However, sufficient data for a later
ime point were not available. Furthermore, aPTT and INR
ere similar in all groups (Table E3).
hromboembolic Events and Survival
iming and frequency of thromboembolic complications
iffered substantially across the groups. HIPA&id/IgG
atients had frequent thromboembolic events occurring pre-
ominantly in the first postoperative month (Table E2).
reedom from total thromboembolic events, including ce-
ebrovascular accidents, TIAs, and peripheral thromboem-
igure 3. Freedom from thromboembolic events during mechani-
al support. HIPA&id/IgG, Heparin-induced platelet activa-
ion assay positive or indeterminate with IgG titers of OD > 1.0;
IT, heparin-induced thrombocytopenia negative; HIPA/
gG,A,M, heparin-induced thrombocytopenia platelet activation
ssay negative and IgG, IgA, or IgM antibodies.olism, was 33%, 33%, and 16% at 1, 3, and 6 months for
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PIPA&id/IgG patients, 77%, 68%, and 55% for HIT
egative (HIPA&id/IgG vs negative, P  .001), and
0%, 53%, and 53% for HIPA/IgG,A,M patients
HIPA&id/IgG vs HIPA/IgG,A,M, P  .068;
IPA/IgG,A,M vs HIT negative, P  .354), respec-
ively (Figure 3). Of note, 9 of 10 patients with a positive
IPA test developed new thrombotic complications. Fur-
her, the relative risk of thromboembolic events in HIT
ositive patients peaked during the first month of MCS
HIPA&id/IgG vs negative and HIPA/IgG,A,M,
dds ratio 7.46; P  .002).
Potential risk factors for thrombotic events until POD 60
re listed in Table 2. Higher titers of anti-PF4/heparin
ntibodies, female gender, and higher mean fibrinogen lev-
ls were independently associated with thrombotic events
Table 3). Diagnosis of “HIPA&id/IgG” cross-corre-
ated with higher titer of anti-PF4/heparin antibodies (R2 
.690; P  .001) and was not simultaneously included in
he multivariate regression model. Validation of the model
howed adequate fit (Hosmer-Lemeshow test; P  .796)
nd satisfactory overall and negative predictive values (Ta-
le E4, Figure E1). Interestingly, no association was found
etween thrombotic events and device type, amount of chest
ube drainage, or transfusion of packed red blood cells,
latelets, and fresh frozen plasma.
The predictive capabilities of various anti-PF4/heparin
ntibody tests with respect to the occurrence of thrombo-
mbolic events until POD 60 were investigated. The com-
ination of EIA GTI and CAA showed satisfactory sensi-
ivity yet lacked specificity (Table E5). Higher titers of
nti-PF4/heparin antibodies by EIA GTI increased specific-
ty at the expense of sensitivity. In contrast, the HIPA assay
n anti-PF4/heparin antibody positive patients yielded a
ABLE 2. Potential risk factors associated with thrombotic
vents during MCS*
Thrombotic event†
ariable Yes No P
IA GTI (pos/neg) 26/19 19/51 .003
IA GTI (OD) 0.91 0.82 0.48 0.39 .001
IPA (yes/no) 9/36 1/69 .006
ender (female/male) 13/32 9/61 .051
ovacor device (yes/no) 11/34 8/62 .077
PTT (s)‡ 46.7 7.0 50.4 8.2 .016
ibrinogen (mg/dL)‡ 572.0 139.6 524.0 121.7 .055
IA GTI (pos/neg), Status of anti–platelet factor 4/heparin antibody by
olyspecific enzyme immunoassay (positive/negative); EIA GTI (OD), titer of
nti–platelet factor 4/heparin antibodies by polyspecific enzyme immuno-
ssay; HIPA, status of heparin-induced platelet activation (yes/no); aPTT,
ctivated partial thromboplastin time. *See Appendix E2 for all variables
ested. †Thrombotic events until postoperative day 60. ‡Mean over 30 days
ostoperatively.ositive predictive value of 90% (Table E5). As expected, p
The Journal of Thoracicensitivity remained low in this setting, indicating an impact
f additional thrombogenic factors other than HIT during
CS.
The frequent and earlier thromboembolic events, how-
ver, did not decrease survival. Freedom from death and
ransplantation at 1, 3, and 6 months was 83%, 58%, and
3%, respectively, in HIPA&id/IgG patients, 68%,
2%, and 27%, respectively, in HIT negative patients
HIPA&id/IgG vs negative, P  .67.), and 78%, 42%,
nd 27%, respectively, in HIPA/IgG,A,M patients
HIPA&id/IgG vs HIPA/IgG,A,M, P  .81). Sim-
lar results were obtained for death or transplantation alone
data not shown).
iscussion
s demonstrated quantitatively in this study, patients
eceiving MCS are more prone to the development of
linical HIT than other cardiac patients. Higher titers of
nti-PF4/heparin antibodies were independently associ-
ted with thromboembolic events. Heparin-induced plate-
et activation and the expression of anti-PF4/heparin IgG
lass antibodies identified patients with an increased risk
or new thromboembolic complications.
nti-PF4/Heparin Antibodies During MCS
nti-PF4/heparin antibodies are frequently observed in pa-
ients undergoing cardiac surgery, but seroconversion was
ot associated with increased risk of thromboembolism in a
rior study.3 HIT develops in only 1% to 3% of patients
fter cardiac surgery despite their high rate of seroconver-
ion.5 Selected studies explain this discrepancy by the
voidance of postoperative heparin administration.3 How-
ver, other studies report the postoperative thrombosis rate
o remain low despite postoperative heparin treatment.5 In
atients receiving MCS, as many as 60% were found to be
nti-PF4/heparin antibody positive.11 Interestingly, about
ne third of anti-PF4/heparin antibody positive patients had
thromboembolism, yet the authors did not note any throm-
otic event in patients without anti-PF4/heparin antibod-
es.11 In contrast, our study clearly documents that the
ABLE 3. Factors independently associated with throm-
otic events*
actor Regression coefficient B (SE) P
igher EIA GTI (OD) 2.454 (0.682) .001
emale gender 4.292 (1.228) .001
igher fibrinogen† .009 (.004) .007
IA GTI (OD), Titer of anti–platelet factor 4/heparin antibodies by polyspe-
ific enzyme immunoassay; OD, optical density; SE, standard error.
Thrombotic events until postoperative day 60. †Mean over 30 days
ostoperatively.atients without PF4/heparin antibodies were at risk for
and Cardiovascular Surgery ● Volume 131, Number 6 1377
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1
CSPew thrombotic complications, although the risk was 7-fold
ower than in antibody-positive patients. Importantly, plate-
ets and coagulation systems during MCS are activated by
he underlying heart failure with impairment of other organ
ystems as well as by the large prosthetic surfaces of the
evices.12,13 The contribution of these factors may in turn
xplain our finding that clinical HIT occurs in as many as
1% of patients receiving MCS. Of note, the diagnosis of
linical HIT was vigorously substantiated by the reference
aboratory remaining blinded to the clinical course of the
atients, showing heparin-induced platelet activation10 and
xpression of IgG classes of anti-PF4/heparin antibodies.14
urthermore, the high number of HIT positive patients
eceiving MCS may be paralleled by patients undergoing
eart transplantation. Indeed, Hourigan and associates15 re-
orted 11 of 46 transplant patients having clinical HIT.
lthough this report has to be interpreted with caution as the
tudy was not supported by platelet functional tests or IgG
lass antibody titers, together with our study it indicates that
he manifestation of clinical HIT could be pronounced in
ajor invasive cardiac procedures such as MCS and heart
ransplantation. Finally, our data are in agreement with
tudies of orthopedic patients, showing that the quantity of
nti-PF4/heparin antibodies correlated with the magnitude
f in vivo coagulation and incidence of thromboembo-
ism.16,17 The higher the titer of anti-PF4/heparin antibod-
es, the more likely were our patients to have thrombotic
vents.
The expression of anti-PF4/heparin antibodies of less
athogenic potential, classified as HIPA/IgG,A,M, is
nother issue clarified by our work. These antibodies were
ound in 25% of patients and had no platelet-activating
roperties. The lack of platelet activation may in turn ex-
lain the similarly low risk of thromboembolism as ob-
erved in anti-PF4/heparin antibody negative patients. Thus,
ifferentiation between clinically relevant anti-PF4/heparin
ntibodies (“HIT antibodies”) and those with minor patho-
enic potential will become essential for patient manage-
ent. Since the commercially available EIAs do not distin-
uish between Ig classes, our study additionally explains
hy some patients with a positive EIA result can develop
hromboembolism whereas others do not. Future investiga-
ions may focus on whether these antibodies can transform
nto “true” HIT antibodies on continuous heparin exposure.
latelet Counts
ur finding that platelet counts did not differ across all
roups deserves consideration. Whereas the drop of plate-
ets until POD 5 was likely due to the use of cardiopul-
onary bypass,5 thereafter, platelet count profiles were
nfluenced by platelet damage during MCS.12,13 Frequent
latelet transfusion may have augmented platelet counts and
hus prevented a second drop of platelet counts after POD 5 a
378 The Journal of Thoracic and Cardiovascular Surgery ● Junhat would otherwise have indicated development of HIT
ntibodies.4 Furthermore, since most patients were exposed
o heparin treatment during their moribund illness, anti-PF4/
eparin antibodies may have been preformed. These pre-
ormed antibodies may in turn induce “rapid-onset HIT” on
epeat heparin exposure, also leading to an early drop of
latelets.18 These possibilities might also explain the rela-
ive increase of platelet counts as percent change from
aseline after POD 10 in HIPA&id/IgG patients. In-
eed, the platelet count profiles indicate an increased
latelet turnover in HIT patients possibly due to elevated
hrombopoietin levels. Additionally, the more pronounced
ncrease of relative platelet counts in HIPA&id/IgG
atients may be consistent with the model of increased
ntravascular platelet activation by pathologically relevant
IT antibodies. Nevertheless, platelet counts were not
ound indicative of HIT in patients receiving MCS. It is an
volving concept that HIT can manifest with a new throm-
otic complication without a major decrease in platelet
ount, as has been shown by a retrospective analysis of 408
IT patients19 and by a prospective cohort study.20
mplications
hese findings have important implications for the manage-
ent of patients receiving MCS and suggest that monitoring
f anti-PF4/heparin antibodies may be relevant to identify-
ng patients with increased risk of thrombotic events.
hromboembolism, for example, cerebrovascular accidents,
s a common issue with an incidence of 6% to 30%.8,21,22
he current study demonstrates that the risk of early throm-
oembolic events was 7-fold higher in anti-PF4/heparin
ntibody positive patients and related to anti-PF4/heparin
ntibody titers. Thromboembolism, while nonfatal in most
ases, was likely to affect morbidity, quality of life, and
osts. Therefore, routine preoperative and postoperative an-
ibody screening by polyspecific EIA and/or CAA is rec-
mmended. Patients without anti-PF4/heparin antibodies
ave a very low likelihood of HIT-associated thromboem-
olism due to the great sensitivity and negative predictive
alue of the tests. However, patients with anti-PF4/heparin
ntibodies should undergo additional assessment of Ig
lasses as well as platelet activating properties. This ap-
roach enhances diagnostic specificity and positive predic-
ive value for new thromboembolic events. We now intro-
uce the HIPA for those purposes, although this complex
est requires strict quality control measures.23 Alternatively,
he serotonin-release assay may be used to confirm heparin-
nduced platelet activation with similar sensitivity and spec-
ficity.6,9,24 However, this test requires the use of radio-
ctive tracers and, therefore, is mostly abandoned in our
nstitutions.
Current heparin alternatives, that is, lepirudin, danap-
roid and argatroban, bear substantial risk of bleeding due to
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CS
Pack of antagonists and difficulties in monitoring.25 Since
nly about 1 of 3 patients with a positive EIA result had
ndeed clinically relevant HIT antibodies, stratification ac-
ording to anti-PF4/heparin Ig classes and HIPA is neces-
ary before heparin is discontinued. Bivalirudin, another
irect thrombin inhibitor and now in clinical trials,26 may be
promising alternative due to its short-acting mechanism by
lood protease cleavage. Further investigations are required
o assess the safety and efficacy of these heparin alternatives
n patients receiving MCS.
imitations
lood samples for detailed analyses of anti-PF4/heparin
ntibodies were available only at PODs 5 to 7. Thus, we
ere unable to investigate the kinetics of antibody produc-
ion and seroconversion over time. Anti-PF4/heparin anti-
odies may be expressed only transiently,18 and patients
hose antibodies disappeared after POD 7 should be at a
ower risk of thromboembolism. In contrast, those patients
n whom antibody titers were detectable only after POD 7
re likely to have a higher risk of thrombotic events. Finally,
ince only frozen samples were available for detailed anal-
ses of anti-PF4/heparin antibodies, test sensitivities of
IA HGW and HIPA may have been too low in some
ases. Thus, the relevance of HIT antibodies may have
ven been underestimated as compared with using fresh
lood samples.
onclusion
IT antibodies were highly prevalent in patients receiving
CS and associated with thromboembolism. In addition to
outine preoperative and postoperative antibody screening,
e recommend platelet activation assays and assessment of
gG class antibody status. Alternative anticoagulants for
atients receiving MCS are necessary so that outcomes can
e improved by preventing heparin-induced complications.
We thank Marlen Ewald, BS (Bad Oeynhausen, Germany),
lrike Strobel, BS, Birgit Fürll, BS, and Carmen Blumentritt, BS
Greifswald, Germany), for superb technical assistance. The Ven-
ricular Assist Device Clinical Team, especially Peter Sarnowski,
N, Daniela Röfe, RN, and Frank Jaschke, RN, provided outstand-
ng care of the patients included in this study. We additionally
hank Kiyotaka Fukamachi, MD, PhD, for reviewing the manu-
cript and Michael Kopcak, Jr, BA (both at The Cleveland Clinic
oundation, Cleveland, Ohio), for editorial advice.
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iscussion
r Harold L. Lazar (Boston, Mass). Twenty-five percent to 50%
f all patients undergoing cardiac surgery will develop antibodies
o heparin, but only 1% to 3% will actually develop the dreaded
IT syndrome. In their study, Dr Schenk and his colleagues have
hown that HIT syndrome may be an important clinical syndrome
n patients receiving MCS, who are routinely exposed to heparin
efore their operation. They have demonstrated that antiheparin
ntibodies developed in 35% of these patients and that these
atients are at higher risk for early thromboembolic events. I have
hree questions for Dr Schenk and his colleagues.
First of all, what type of heparin did these patients receive?
revious studies have shown that the incidence of positive heparin
ntibodies can be reduced by as much as a third by using pork
nstead of beef heparin. In your study did you notice any difference
etween pork and beef heparin and the incidence of thromboem-
olic events?
Dr El-Banayosy. We are using pork heparin in all of our
atients.
Dr Lazar. Second, in your study you used both the enzyme-
inked immunosorbent assay and the CAA to detect antiplatelet
ntibodies and thromboelastography to detect hypercoagulability.
ince the decision to discontinue heparin is very important and the
evelopment of the thromboembolic event is devastating to these
atients, on the basis of your data, what tests would you use to
etermine when heparin should be avoided, and would you rec-
mmend obtaining these tests in all patients before putting them on
CS devices?
Dr Schenk. We know that about 50% of all patients have
ntibodies, but only 1% to 3% of those patients have the clinical
IT symptoms. We also know that there are several immuno-
lobulins, for example, IgG, IgA, and IgM, that are relevant, and,
s you mentioned, those tests only assess the overall number of
hose antibodies. We cannot distinguish among IgA, IgG, and IgM
y the commercially available tests.
As to your point, we have to look for the presence of the
linically relevant antibodies, and we would also now add some
dditional testing. For example, we would add some platelet func-
ion tests, which can distinguish between those antibodies that are
ore pathogenic versus the others. That has been introduced now;
nfortunately, we did not do that during the time frame of our
tudy period.
The decision to discontinue heparin and to switch to another
ntravenous anticoagulant is based on an evaluation of all available
aboratory tests together with clinical signs suggestive of HIT. If
latelet counts have not recovered, oral anticoagulants should not
e administered. If the patient no longer has low platelet counts,
ral anticoagulants can be used as the clinical situation requires,
nd we do this with thromboelastogram guidance.
Dr Lazar. Finally, in view of your poor results with lepirudin
nd the platelet aggregate inhibitors, what therapeutic agents u
380 The Journal of Thoracic and Cardiovascular Surgery ● Junould you recommend for patients when heparin must be discon-
inued? Do you have any experience with bivalirudin (Angiomax),
hich seems to be used increasingly by our interventional cardi-
logists during angioplasty procedures for acute coronary syn-
romes?
Dr Schenk. Unfortunately, as of now we have not used the
rug that you mentioned, but in our current patients we are using
epirudin, which is an analogous agent to bivalirudin. However, we
id observe many side effects, and most of the time we are very
oncerned about bleeding complications. We observed many pa-
ients who did receive lepirudin and had bleeding complications.
When we have a patient with these antibodies, we try to give
latelet stabilizing factors as soon as we can. For instance, there is
ne drug named dipyridamole (Persantine), and because that seems
o stabilize platelet function, it may be especially useful in cases of
IT. In addition, we try to give aspirin and clopidogrel as well,
hich may have beneficial effects.
Dr Ralph Damiano (St Louis, Mo). Could you comment on
our strategies in the patients who were HIT positive? I assume a
umber of these patients were bridged to transplant. Did you find
higher mortality at the time of the transplantation, and what were
our strategies for managing the patients during that period?
Dr Schenk. The first part of your question concerns outcome
elated to survival. We did not see any difference in survival. Why
hat is, we do not know yet, but there was no difference in survival
etween antibody positive and negative patients.
The second part of your question concerns what we give if the
atient has had HIT antibodies before. What do we do during
ransplant? HIT antibodies are transiently expressed. As long as
ou use heparin, the patient obviously is at risk. However, if you
iscontinue heparin, then those antibodies will likely disappear. If
ou re-evaluate those antibodies after 12 to 18 months when the
atient is coming back for transplant, most of the time those
ntibodies are not effective anymore. Therefore, if you have a
atient who had a history of HIT but has no current antibodies,
here is no reason not to give heparin during cardiopulmonary
ypass. Of course, you have to screen those antibodies closely, and
s soon as antibodies come back, you had better give something
lse.
Dr Steven Bolling (Ann Arbor, Mich). Your unit uses many
ifferent types of circulatory support. Was there a different rate of
IT positivity associated with different ventricular assist or circu-
atory support devices? Were there heparin-bonded surfaces in
hese devices? The numbers may be small.
Dr Schenk. Thank you very much. This is a pretty important
uestion because it emphasizes the pathology of that disease. We
o not believe that this is device-related. Of course, we cannot
rove that because we would have to have higher numbers and do
multivariable analysis. However, the only factor that is known to
ause HIT is obviously heparin, and even if one device is found to
e more related to HIT than the other, it is our belief that this is
ore treatment-related than device-related. I agree with you that
IT may be more prevalent with certain devices, but this should be
elated to the clinical indication for the device. For example, our
atients who receive a CardioWest total artificial heart (SynCardia
ystems, Inc, Tucson, Ariz) are among the sickest. They are
sually receiving extracorporeal membrane oxygenation, they are
sually in cardiogenic shock, and they are likely to be in the
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xposure as well. If you see a higher incidence of HIT positive
atients, for example, with this particular device, then I think this
s a matter of whether and how much heparin you gave before
mplant.
In addition, there is also reason to believe that there is an
nalogy to the HLA sensitization. There was a study done by the
leveland Clinic last year. When they compared their HeartMate
Thoratec Corporation, Pleasanton, Calif) versus Novacor (World-
eart Corporation, Oakland, Calif) data, they found that HLA
ensitization was essentially not device-related; it was treatment-
elated, essentially a matter of the number of blood products used
nd not contingent on the device at all. So one thought I come back
o is this: heparin is given before, during, and after surgery and
herefore those antibodies may be produced in quite a number and
ith better specificity and for a longer time. I think it stands to
eason that heparin is the only factor that causes HIT syndrome.
n the other hand, since so much heparin is given, the likelihood
f having HIT syndrome is probably among the highest in patients
eceiving MCS.
Dr El-Banayosy. I would like to make a short comment on
hat. Regarding the differences between the devices, we found that
e had a higher incidence in the patients supported with the
ardioWest total artificial heart. It might be due to the fact that the
atients supported with a total artificial heart in our institution are
he sickest cohort of patients and they have received heparin
onger. But the numbers, as I mentioned, were not too high to
llow us to see a statistically significant difference.
Dr Keith Allen (Indianapolis, Ind). I enjoyed your talk. Our
roup has had the opportunity to participate in some controlled
rials using bivalirudin as an alternative to heparin. You suggested f
The Journal of Thoracicn one of your answers that in using lepirudin, which is one of the
hree direct thrombin inhibitors that are available, you had in-
reased bleeding complications. I would like the audience to
nderstand that the three direct thrombin inhibitors are not created
qual. The problem you are having with lepirudin is related to its
onger half-life and the inability to have any type of marker to
easure the degree of anticoagulation. Bivalirudin has a shorter
alf-life and its anticoagulation can be measured. Therefore, I
ould argue that bivalirudin is a very attractive alternative to
eparin in a patient with a left ventricular assist device.
Dr Eric A. Rose (New York, NY). There have been devices that
ave actually been designed to include a heparin coating on them.
ne such device that we have worked with is the MicroMed
eBakey device (MicroMed Technology, Inc, Houston, Tex). Af-
er review of outcomes looking at the heparin-coated versus the
oncoated devices, we actually reached the conclusion that it
ffered no advantage and perhaps a disadvantage. Essentially, a
evice that is coated with heparin is almost potentially a heparin
accine, and I think that is an important issue that needs to be part
f device design.
Dr Schenk. Maybe I can add a dissenting point. In a study
rom the Berlin group done about 3 years ago, the Berlin Heart
Berlin Heart AG, Berlin, Germany), which is heparin-coated,
as compared with other devices that are not. The Berlin group
id not find any higher incidence of heparin antibodies between
he groups with coated versus noncoated tubing. This actually
ould argue against the statement or against this idea that
eparin coating is a bad thing to do. I think it is reasonable to
ay that heparin that is bound to a device may not be as
mmunogenic as heparin that is unfractionated and streams
reely in the blood.
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CSPppendix E1
he following devices were used: CardioWest Total Artificial
eart (SynCardia Systems, Tucson, Ariz) (n  49), Thoratec
entricular Assist Device (Thoratec Corporation, Pleasanton,
alif) (n  27), Novacor Left Ventricular Assist System (World-
eart Corporation, Oakland, Calif) (n  20), Terumo DuraHeart
eft Ventricular Assist System (Terumo Heart Incorporation, Ann
rbor, Mich) (n  10), Berlin Heart INCOR Ventricular Assist
evice (Berlin Heart AG, Berlin, Germany) (n  4), HeartMate
E Left Ventricular Assist System (Thoratec Corporation) (n 
), Medos HIA-Ventricular Assist Device (Medos, Stolberg, Ger-
any) (n  2), Arrow LionHeart Left Ventricular Assist System
Arrow International, Reading, Pa) (n  2), Thoratec Implantable
entricular Assist Device [IVAD] (Thoratec Corporation) (n 1),
nd the CorAide Left Ventricular Assist System (Arrow Interna-381.e1 The Journal of Thoracic and Cardiovascular Surgery ● Jional) (n  1). Four patients received multiple devices: a Thor-
tec, Novacor and CorAide devices were replaced by a Cardio-
est total artificial heart, and a HeartMate left ventricular assist
evice was aided by a Thoratec right ventricular assist device.
ppendix E2
ariables considered being associated with thrombotic events:
nti-PF4 heparin antibodies, heparin-induced platelet activa-
ion, gender, age, device type, site of mechanical assistance/
eplacement, aPTT, INR, fibrinogen, blood loss, packed red
lood cells, fresh frozen plasma, units of platelets, surgical
e-exploration, reoperation, preimplant continuous venovenous
emofiltration, preimplant extracorporeal membrane oxygen-
tion, preimplant ventilation, preoperative intra-aortic balloon
ump, etiology, and diabetes.une 2006
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PABLE E1. Patient characteristics
Variable n  115
Demography
Female 22 (19%)
Age (y; mean  SD) 54.1  14.9
Body surface area (m2; mean  SD) 1.9  0.2
Medical history
Ischemic cardiomyopathy 54 (47%)
Dilated cardiomyopathy 34 (30%)
Prior thoracic surgery 40 (35%)
Preoperative support
Inotropes 110 (96%)
IABP/ECMO 60 (52%)
CVVH 34 (30%)
Mechanical ventilation 53 (46%)
Surgery and postoperative course
Blood loss* (mL; mean  SD [15th, 85th percentiles]) 826 811 [245, 1545]
Packed red blood cells† (units/10 days; mean  SD [15th, 85th percentiles]) 14.6 11.1 [4, 26]
Fresh frozen plasma† (units; mean  SD [15th, 85th percentiles]) 5.7 8.9 [0, 12]
Platelets† (units; mean  SD [15th, 85th percentiles]) 1.8 2.8 [0, 5]
Re-exploration for bleeding 40 (35%)
D, Standard deviation; IABP, intra-aortic balloon pump; ECMO, extracorporal membrane oxygenation; CVVH, continuous venovenous hemofiltration.
Within 12 hours after surgery. †Within 10 days after surgery.
ABLE E2. Anti-PF4/heparin antibodies, heparin-induced platelet activation, platelets, aPTT, and thrombotic events in HIT
ositive patients
EIA HGW aPTT Platelets
t.
o.
EIA
GTI IgG IgA IgM HIPA POD 7 POD 14 POD 21 POD 7 POD 14 POD 21 Event POD Treatment*
1 1.973 1.744 0.245 0.965 pos 54 45 89 251 662 211 TIA 14 Not detected
2 1.215 1.562 0.330 0.350 pos 38 32 30 142 318 248 TIA  CVA 23/27 Epoprostenol
3 1.482 1.089 1.491 0.274 pos 35 40 50 371 416 353 TIA 21 Lepirudin
4 0.839 1.032 0.256 0.507 pos 63 71 75 55 304 221 CVA 25 Not detected
5 2.392 1.899 1.632 0.346 pos 49 33 30 79 270 213 CVA 25 Epoprostenol
6 1.599 1.804 0.464 0.659 pos 51 53 45 37 89 262 None Not detected
7 0.503 1.254 0.273 0.282 id 55 59 54 90 218 217 None Not detected
8 2.291 1.915 1.361 0.671 pos 47 33 30 56 64 139 TIA  CVA 11/12 ASA/phenprocoumon
9 0.485 0.716 0.447 0.453 pos 53 38 41 68 59 34 Limb ischemia 11 Lepirudin
10 2.212 1.913 1.726 0.385 pos 63 46 57 40 168 205 CVA 24 Not detected
11 2.024 1.819 0.46 0.700 pos 47 42 34 47 166 214 TIA 30 Lepirudin
12 1.604 1.320 1.777 1.746 id 64 41 61 53 54 184 CVA 21 Not detected
IA GTI, Anti-PF/heparin antibody by polyspecific enzyme immunoassay (titer); EIA HGW, anti-PF/heparin antibody classes by monospecific enzyme
mmunoassay (titer); HIPA, status of heparin-induced platelet activation (positive/indeterminate [pos/id]); aPTT, activated partial thromboplastin time; POD,
ostoperative day; TIA, transient ischemic attack; CVA, cerebrovascular accident. *Treatment with alternative anticoagulation on diagnosis during hospital
tay. Note that in 6 patients the condition remained undetected during their hospital stay, resulting in their receiving heparin.
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CSPABLE E3. Standard coagulation monitoring
POD 3 POD 7 POD 10 POD 14 POD 21 POD 28
ibrinogen (n)* (12/28/73) (11/28/69) (10/24/64) (11/17/48) (8/14/36) (6/9/32)
IPA&id/IgG 575 (470; 691) 618 (521; 729) 660 (555; 765) 511 (417; 606) 566 (475; 657) 586 (439; 739)
IPA/IgG,A,M 553 (484; 624) 614 (565; 663) 614 (549; 678) 573 (476; 670) 571 (467; 676) 567 (433; 700)
IT neg 537 (501; 573) 568 (523; 612) 569 (524; 614) 587 (526; 648) 536 (465; 607) 514 (449; 579)
.721 .371 .218 .523 .810 .538
DIM (n)* (12/24/62) (12/28/71)
IPA&id/IgG 1004 (519; 1488) 1183 (563; 1802)
IPA/IgG,A,M 898 (533; 1262) 1460 (827; 2092)
IT neg 694 (566; 829) 843 (645; 1041)
.189 .042
NR (n)* (12/28/73) (11/28/73) (11/24/69) (12/21/62) (11/21/51) (9/17/40)
IPA&id/IgG 1.12 (1.00; 1.25) 1.47 (0.96; 1.99) 1.66 (0.93; 2.40) 1.52 (1.06; 1.98) 1.67 (1.10; 2.24) 2.01 (1.29; 2.74)
IPA/IgG,A,M 1.44 (1.11; 1.77) 1.50 (1.20; 1.79) 1.34 (1.11; 1.56) 1.28 (1.13; 1.42) 1.41 (1.18; 1.65) 1.42 (1.17; 1.67)
IT neg 1.38 (1.23; 1.53) 1.39 (1.24; 1.54) 1.30 (1.20; 1.40) 1.29 (1.19; 1.39) 1.48 (1.24; 1.71) 1.70 (1.41; 1.99)
.394 .774 .131 .233 .665 .205
PTT (n)* (12/28/73) (12/28/73) (11/23/70) (12/21/60) (10/21/52) (9/17/40)
IPA&id/IgG 42 (35; 49) 46 (38; 54) 47 (37; 56) 46 (38; 55) 47 (35; 60) 45 (35; 54)
IPA/IgG,A,M 44 (40; 47) 51 (54; 56) 53 (46; 59) 47 (42; 52) 51 (45; 57) 56 (36; 75)
IT neg 45 (42; 47) 51 (46; 56) 48 (45; 51) 51 (48; 54) 51 (47; 55) 51 (45; 56)
.749 .754 .303 .295 .784 .516
OD, Postoperative day; DDIM, D-dimers; INR, international normalized ratio; aPTT, activated partial thromboplastin time; HIPA&id/IgG, heparin-
nduced platelet activation assay positive or indeterminate with IgG titers of OD  1.0; HIT, heparin-induced thrombocytopenia negative; HIPANEG/
gG,A,M, heparin-induced thrombocytopenia platelet activation assay negative and IgG, IgA, and IgM antibodies. *Number of patients for whom data are
vailable (HIPA&id/IgG/ HIPA/IgG,A,M/HIT negative).
ABLE E4. Classification table for multivariate regression model*
Predicted
Selected cases† Unselected cases†
bserved
Thrombotic events
within 2 months % correct
Thrombotic events
within 2 months % correct
hrombotic events within 2 months
No 41 3 93.2 30 6 83.3
Yes 5 14 73.7 6 9 60.0
verall % 87.3 76.5
Forward stepwise inclusion of all variables. Variables were retained at P  .05. Similar results were obtained by backward stepwise elimination of
ariables (data not shown). †Bernoulli distribution.
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CS
PFigure E1. Receiver operating characteristic (ROC) curve for multivariate regression model to predict throm-
botic events. Area under curve 0.885  0.037 (0.813; 0.956); P < .001. Regression equation: z  9.017 
2.454 · b1  4.292 · b2  0.009 · b3, where b1 is titer of anti-PF4/heparin antibodies by polyspecific enzyme
immunoassay (OD), b2 is gender (1, female; 0, male), and b3 is fibrinogen (mg/dL).
able E5. Predictive capabilities of anti-PF4/heparin antibody tests for thromboembolic events
EIA GTI
(OD > 0.5)
EIA GTI
(OD > 1.0)
EIA GTI (OD > 0.5)
or CAA > 1
EIA GTI (OD > 0.5)
or CAA > 1 and
IgG (OD > 1.0)
EIA GTI (OD > 0.5)
or CAA > 1 and
HIPA positive
ensitivity 0.69 0.42 0.81 0.38 0.31
pecificity 0.69 0.93 0.51 0.84 0.97
redictive value 0.52 0.75 0.44 0.73 0.90
ositive (95% CI) (0.41; 0.61) (0.53; 0.90) (0.36; 0.49) (0.48; 0.91) (0.57; 0.99)
redictive value 0.83 0.77 0.84 0.65 0.64
egative (95% CI) (0.74; 0.89) (0.72; 0.80) (0.73; 0.93) (0.57; 0.70) (0.58; 0.66)
.001 .001 .004 .021 .005
IA GTI, Anti-PF/heparin antibody by polyspecific enzyme immunoassay (OD- titer); HIPA, status of heparin-induced platelet activation (positive/negative);
AA, column agglutination assay (grade 0-3); Ig, immunoglobulin; CI, confidence interval.
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